Intravesical therapy with vinorelbine tartrate: antitumor activity in orthotopic murine cell carcinoma of the bladder

• Published in: The Journal of urology Vol. 158; no. 3 Pt 1; p. 912
• Main Authors: Bonfil, R D, Russo, D M, Schmilovich, A J, Garcia-Palazzo, I B
• Format: Journal Article
• Language: English
• Published: United States 01-09-1997
• Subjects: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic - administration & dosage; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - mortality; Female; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - mortality; Vinblastine - administration & dosage; Vinblastine - analogs & derivatives
• ISSN: 0022-5347
• DOI: 10.1016/S0022-5347(01)64363-5

To ascertain intravesical vinorelbine tartrate (VNR) antitumor activity against MB-49, a murine transitional cell carcinoma of the bladder (TCC), in an in vivo setting.
C57B1/6J female mice were intravesically implanted with 5 x 10(4) MB-49 cells and treated locally with VNR. Tumor incidence and volume analyses, as well as survival studies were carried out.
Tumor incidence was significantly lower in VNR-treated mice (48%, n = 23) than in controls (84%, n = 19), as evaluated sixteen days after MB-49 orthotopic inoculation. Intravesical tumor volume was also significantly smaller in treated mice respect to controls (median [range]: 0.5 [0.4 to 61.8] mm.3 versus 47.7 [4.2 to 179.7] mm.3 respectively, p < 0.001 Kruskal-Wallis test). Median survival duration of the animals treated with VNR was 68 [21 to 68] days, and was significantly greater (p = 0.01, Kruskal-Wallis test) than that of untreated controls (18 [16 to 20] days).
Intravesical VNR treatment demonstrated an evident antitumor effect against the TCC model assayed. The results obtained suggest a potential use of VNR as intravesical treatment for superficial TCC following transurethral bladder tumor resection to prevent recurrence or retard tumor growth.